Total Payments
$440.81
2022 Payments
$340.00
Companies
6
Transactions
8
Medicare Patients
4,603
Medicare Billing
$2.1M
Payment Breakdown by Category
Research$319.00 (72.4%)
Education$64.82 (14.7%)
Food & Beverage$56.99 (12.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $319.00 | 1 | 72.4% |
| Education | $64.82 | 4 | 14.7% |
| Food and Beverage | $56.99 | 3 | 12.9% |
Payments by Type
Research
$319.00
1 transactions
General
$121.81
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $319.00 | 1 | $0 (2022) |
| PFIZER INC. | $52.90 | 3 | $0 (2022) |
| Genentech USA, Inc. | $24.73 | 1 | $0 (2017) |
| Novocure Inc. | $16.16 | 1 | $0 (2021) |
| Rigel Pharmaceuticals, Inc. | $16.10 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $340.00 | 2 | Eli Lilly and Company ($319.00) |
| 2021 | $49.08 | 3 | PFIZER INC. ($21.00) |
| 2020 | $16.10 | 1 | Rigel Pharmaceuticals, Inc. ($16.10) |
| 2019 | $10.90 | 1 | PFIZER INC. ($10.90) |
| 2017 | $24.73 | 1 | Genentech USA, Inc. ($24.73) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $319.00 | Research |
| Study: POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | ||||||
| 09/19/2022 | PFIZER INC. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2021 | PFIZER INC. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2021 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $16.16 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 06/16/2020 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Hematology | ||||||
| 04/11/2019 | PFIZER INC. | BESPONSA (Biological) | Education | In-kind items and services | $10.90 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2017 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $319.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 1,335 | 39,005 | $2.2M | $861,150 |
| 2022 | 35 | 1,515 | 51,779 | $2.4M | $942,213 |
| 2021 | 13 | 819 | 7,376 | $616,165 | $161,983 |
| 2020 | 17 | 934 | 2,515 | $496,462 | $110,098 |
Total Patients
4,603
Total Services
100,675
Medicare Billing
$2.1M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 16,000 | $1.2M | $675,123 | 55.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 260 | 595 | $193,132 | $57,767 | 29.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 85 | 301 | $159,530 | $32,491 | 20.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 236 | 408 | $88,808 | $27,605 | 31.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 73 | 120 | $53,769 | $15,782 | 29.4% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 16 | 62 | $68,200 | $13,352 | 19.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 60 | 183 | $32,025 | $4,357 | 13.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 31 | 79 | $19,750 | $4,210 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $14,150 | $4,086 | 28.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 64 | 77 | $10,196 | $3,080 | 30.2% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 14 | 938 | $14,070 | $3,055 | 21.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 31 | $8,060 | $2,911 | 36.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 46 | $17,940 | $2,436 | 13.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $8,190 | $2,290 | 28.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 34 | $5,950 | $2,093 | 35.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 48 | 123 | $15,375 | $1,563 | 10.2% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 16 | 763 | $7,249 | $1,390 | 19.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 22 | 53 | $6,095 | $1,231 | 20.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 104 | $9,360 | $1,187 | 12.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 42 | 1,070 | $32,100 | $904.11 | 2.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 17 | 21 | $1,995 | $834.75 | 41.8% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 15 | 96 | $23,520 | $666.80 | 2.8% |
| J9263 | Injection, oxaliplatin, 0.5 mg | Office | 2023 | 13 | 11,500 | $149,500 | $639.47 | 0.4% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 13 | 36 | $4,140 | $586.44 | 14.2% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2023 | 19 | 4,512 | $6,768 | $458.57 | 6.8% |
About Dr. Frederick Briccetti, MD
Dr. Frederick Briccetti, MD is a Hematology & Oncology healthcare provider based in Concord, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063406932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frederick Briccetti, MD has received a total of $440.81 in payments from pharmaceutical and medical device companies, with $340.00 received in 2022. These payments were reported across 8 transactions from 6 companies. The most common payment nature is "" ($319.00).
As a Medicare-enrolled provider, Briccetti has provided services to 4,603 Medicare beneficiaries, totaling 100,675 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Concord, NH
- Active Since 09/07/2005
- Last Updated 02/15/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063406932
Products in Payments
- ORGOVYX (Drug) $42.00
- Perjeta (Biological) $24.73
- Optune (Device) $16.16
- Tavalisse (Drug) $16.10
- BESPONSA (Biological) $10.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Concord
Dr. Sudhathi Chichili, M.d, M.D
Hematology & Oncology — Payments: $21,182
Hematology & Oncology $21,182
Dr. Walailuk Chaiyarat, Md, MD
Hematology & Oncology — Payments: $19,417
Hematology & Oncology $19,417
Dr. Elizabeth Odumakinde, M.d, M.D
Hematology & Oncology — Payments: $17,590
Hematology & Oncology $17,590
Dr. Lesley Martin, M.d, M.D
Hematology & Oncology — Payments: $7,915
Hematology & Oncology $7,915
Jeanna Walsh, Md, MD
Hematology & Oncology — Payments: $3,449
Hematology & Oncology $3,449
Meghan Steiner, Md, MD
Hematology & Oncology — Payments: $1,234
Hematology & Oncology $1,234